Skip to content
2000
  1. Home
  2. A-Z Publications
  3. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry - Anti-Cancer Agents)
  4. Fast Track Articles
  5. Fast Track Article
image of Quinacrine Inhibits Hepatocellular Carcinoma Growth and Enhances the Anti-HCC Effects of Lenvatinib

Abstract

Background

Hepatocellular Carcinoma (HCC) is a highly prevalent cancer worldwide, necessitating effective treatment options. However, current treatments do not provide satisfactory results. Quinacrine, a synthetic drug belonging to the 9-aminoacridine family, has demonstrated promising antitumor effects.

Objective

The objective of the current study is to evaluate the anti-HCC effect of Quinacrine and explore whether quinacrine can improve the anti-HCC response of lenvatinib and .

Methods

The HepG2 and MHCC-97H cells were treated with Quinacrine. Cell proliferation and cell apoptosis were assessed using the Cell Counting Kit-8 (CCK8) Assay, Colony Formation Assay, and Annexin V/7-AAD staining method. The invasion and migratory ability of HepG2 and MHCC-97H cells were assessed by Transwell Assay. The level of ROS of HCC cells was measured using a ROS-kit by Flow cytometric analysis. Besides, an study was performed in the Balb/c nude mice bearing MHCC-97H tumors to analyze the function of Quinacrine in tumor growth.

Results

Quinacrine can decrease cell viability in HepG2 and MHCC-97H cells, but not affect LO2 cells. Quinacrine impaired the colony formation, invasion and migratory ability in half-maximal inhibitory concentration (IC50). Quinacrine also significantly induced apoptosis in HepG2 and MHCC-97H cells in a concentration-dependent manner. On the one hand, ROS was significantly up-regulated in HCC cells after quinacrine treatment. On the other hand, We found quinacrine blocked autophagy flux in HepG2 and MHCC-97H cells. Moreover, Quinacrine significantly enhances the anti-HCC efficacy of lenvatinib . In the mouse MHCC-97H model, We found that combination therapy with Quinacrine and lenvatinib resulted in a smaller tumor volume and weight than inoculated with lenvatinib alone.

Conclusion

Our findings demonstrated that quinacrine exerts anti-HCC effects and sensitizes hepatocellular carcinoma to lenvatinib. Collectively, our study provides novel therapeutic insights for managing HCC and offers a valuable strategy for future clinical interventions in this field.

© 2025 Bentham Science Publishers
Loading

Article metrics loading...

/content/journals/acamc/10.2174/0118715206304652241105063112
2025-01-22
2025-03-29

  • From This Site

    /content/journals/acamc/10.2174/0118715206304652241105063112
    dcterms_title,dcterms_subject,pub_keyword
    -contentType:Contributor -contentType:Concept -contentType:Institution
    10
    5
Loading full text...

Full text loading...

References

  1. Toh M.R. Wong E.Y.T. Wong S.H. Ng A.W.T. Loo L.H. Chow P.K.H. Ngeow J. Global epidemiology and genetics of hepatocellular carcinoma. Gastroenterology 2023 164 5 766 782 10.1053/j.gastro.2023.01.033 36738977
    [Google Scholar]
  2. Anwanwan D. Singh S.K. Singh S. Saikam V. Singh R. Challenges in liver cancer and possible treatment approaches. Biochim. Biophys. Acta Rev. Cancer 2020 1873 1 188314 10.1016/j.bbcan.2019.188314 31682895
    [Google Scholar]
  3. Chen S. Cao Q. Wen W. Wang H. Targeted therapy for hepatocellular carcinoma: Challenges and opportunities. Cancer Lett. 2019 460 1 9 10.1016/j.canlet.2019.114428 31207320
    [Google Scholar]
  4. Llovet J.M. Kelley R.K. Villanueva A. Singal A.G. Pikarsky E. Roayaie S. Lencioni R. Koike K. Zucman-Rossi J. Finn R.S. Hepatocellular carcinoma. Nat. Rev. Dis. Primers 2021 7 1 6 10.1038/s41572‑020‑00240‑3 33479224
    [Google Scholar]
  5. Cucarull B. Tutusaus A. Rider P. Hernáez-Alsina T. Cuño C. García de Frutos P. Colell A. Marí M. Morales A. Hepatocellular carcinoma: Molecular pathogenesis and therapeutic advances. Cancers (Basel) 2022 14 3 621 10.3390/cancers14030621 35158892
    [Google Scholar]
  6. Fornari F. Giovannini C. Piscaglia F. Gramantieri L. Elucidating the molecular basis of sorafenib resistance in HCC: Current findings and future directions. J. Hepatocell. Carcinoma 2021 8 741 757 10.2147/JHC.S285726 34239844
    [Google Scholar]
  7. Oien D.B. Pathoulas C.L. Ray U. Thirusangu P. Kalogera E. Shridhar V. Repurposing quinacrine for treatment-refractory cancer. Semin. Cancer Biol. 2021 68 21 30 10.1016/j.semcancer.2019.09.021 31562955
    [Google Scholar]
  8. Wang Y. Bi Q. Dong L. Li X. Ge X. Zhang X. Fu J. Wu D. Li S. Quinacrine enhances cisplatin-induced cytotoxicity in four cancer cell lines. Chemotherapy 2010 56 2 127 134 10.1159/000313525 20407239
    [Google Scholar]
  9. Yang C. Zhang H. Zhang L. Zhu A.X. Bernards R. Qin W. Wang C. Evolving therapeutic landscape of advanced hepatocellular carcinoma. Nat. Rev. Gastroenterol. Hepatol. 2023 20 4 203 222 10.1038/s41575‑022‑00704‑9 36369487
    [Google Scholar]
  10. Song M. Ma L. Shen C. Liu W. Zhang P. Bi R. Zhao C. FGD5-AS1/miR-5590-3p/PINK1 induces Lenvatinib resistance in hepatocellular carcinoma. Cell. Signal. 2023 111 110828 10.1016/j.cellsig.2023.110828 37517671
    [Google Scholar]
  11. Chen Y. Hu H. Yuan X. Fan X. Zhang C. Advances in immune checkpoint inhibitors for advanced hepatocellular carcinoma. Front. Immunol. 2022 13 896752 10.3389/fimmu.2022.896752 35757756
    [Google Scholar]
  12. Jin H. Shi Y. Lv Y. Yuan S. Ramirez C.F.A. Lieftink C. Wang L. Wang S. Wang C. Dias M.H. Jochems F. Yang Y. Bosma A. Hijmans E.M. de Groot M.H.P. Vegna S. Cui D. Zhou Y. Ling J. Wang H. Guo Y. Zheng X. Isima N. Wu H. Sun C. Beijersbergen R.L. Akkari L. Zhou W. Zhai B. Qin W. Bernards R. EGFR activation limits the response of liver cancer to lenvatinib. Nature 2021 595 7869 730 734 10.1038/s41586‑021‑03741‑7 34290403
    [Google Scholar]
  13. Zipper J. Dabancens A. Guerrero A. Trujillo V. Quinacrine revised. Hum. Reprod. Update 1995 1 4 324 342 10.1093/humupd/1.4.324 9080211
    [Google Scholar]
  14. Etman S.M. Mehanna R.A. Bary A.A. Elnaggar Y.S.R. Abdallah O.Y. Undaria pinnatifida fucoidan nanoparticles loaded with quinacrine attenuate growth and metastasis of pancreatic cancer. Int. J. Biol. Macromol. 2021 170 284 297 10.1016/j.ijbiomac.2020.12.109 33340624
    [Google Scholar]
  15. Lobo M.R. Green S.C. Schabel M.C. Gillespie G.Y. Woltjer R.L. Pike M.M. Quinacrine synergistically enhances the antivascular and antitumor efficacy of cediranib in intracranial mouse glioma. Neuro-oncol. 2013 15 12 1673 1683 10.1093/neuonc/not119 24092859
    [Google Scholar]
  16. Abdulghani J. Gokare P. Gallant J.N. Dicker D. Whitcomb T. Cooper T. Liao J. Derr J. Liu J. Goldenberg D. Finnberg N.K. El-Deiry W.S. Sorafenib and quinacrine target anti-apoptotic protein MCL1: A poor prognostic marker in Anaplastic Thyroid Cancer (ATC). Clin. Cancer Res. 2016 22 24 6192 6203 10.1158/1078‑0432.CCR‑15‑2792 27307592
    [Google Scholar]
  17. Du D. Liu C. Qin M. Zhang X. Xi T. Yuan S. Hao H. Xiong J. Metabolic dysregulation and emerging therapeutical targets for hepatocellular carcinoma. Acta Pharm. Sin. B 2022 12 2 558 580 10.1016/j.apsb.2021.09.019 35256934
    [Google Scholar]
  18. Kudo M. Finn R.S. Qin S. Han K.H. Ikeda K. Piscaglia F. Baron A. Park J.W. Han G. Jassem J. Blanc J.F. Vogel A. Komov D. Evans T.R.J. Lopez C. Dutcus C. Guo M. Saito K. Kraljevic S. Tamai T. Ren M. Cheng A.L. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: A randomised phase 3 non-inferiority trial. Lancet 2018 391 10126 1163 1173 10.1016/S0140‑6736(18)30207‑1 29433850
    [Google Scholar]
  19. Zhu X.D. Sun H.C. Emerging agents and regimens for hepatocellular carcinoma. J. Hematol. Oncol. 2019 12 1 110 10.1186/s13045‑019‑0794‑6 31655607
    [Google Scholar]
  20. Zheng Y. Huang C. Lu L. Yu K. Zhao J. Chen M. Liu L. Sun Q. Lin Z. Zheng J. Chen J. Zhang J. STOML2 potentiates metastasis of hepatocellular carcinoma by promoting PINK1-mediated mitophagy and regulates sensitivity to lenvatinib. J. Hematol. Oncol. 2021 14 1 16 10.1186/s13045‑020‑01029‑3 33446239
    [Google Scholar]
/content/journals/acamc/10.2174/0118715206304652241105063112
Loading
Quinacrine Inhibits Hepatocellular Carcinoma Growth and Enhances the Anti-HCC Effects of Lenvatinib
Bentham Science Publishers ; https://doi.org/10.2174/0118715206304652241105063112
/content/journals/acamc/10.2174/0118715206304652241105063112
/content/journals/acamc/10.2174/0118715206304652241105063112
Loading

Data & Media loading...


  • Article Type:     Research Article
Keywords: lenvatinib ; strategy ; Hepatocellular carcinoma (HCC) ; therapeutic ; ROS ; quinacrine

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test